Even more speculative, the alpha ERD differences at the third visit, shown at Fp1 and Fp2, are localized to the orbitofrontal cortex, a location where amyloid and tau pathology is concentrated in Alzheimer’s disease (AD) [80–82], another point connecting mTBI to the known increased risk of subsequent AD and general cognitive deficits [3]. The gene discussed is MAPT; the disease is amyloidosis.